GLP-1 Agonist Liraglutide Significantly Decreases CV Risk and Mortality: Full Results From LEADER Presented
The GLP-1 agonist liraglutide has been shown to significantly decrease the risk of major cardiovascular events and death from any cause over a 3-year period: a 13% relative risk reduction, when compared with placebo as add-on therapy, according to results from the LEADER trial presented at the annual meeting of the American Diabetes Association (ADA). […]